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Background: The anti-tumor lipid edelfosine 
alters lipid raft integrity. How this signals 
inhibition of growth is not understood. 
Results: Disruption of plasma membrane domain 
organization triggers the selective removal of lipid 
raft associated transporters altering pH 
homeostasis. 
Conclusion: Raft integrity controls pH 
homeostasis and growth.  
Significance: Choline-containing lysolipid 
analogues induce biophysical modifications of 
microdomains leading to inhibition of cell growth 
through alteration of pH homeostasis. 
 
 The lysophosphatidylcholine analogue 
edelfosine is a potent antitumor lipid that 
targets cellular membranes. The underlying 
mechanisms leading to cell death remain 
controversial, although two cellular membranes 
have emerged as primary targets of edelfosine: 
the plasma membrane (PM) and the 
endoplasmic reticulum. In an effort to identify 
conditions that enhance or prevent the 
cytotoxic effect of edelfosine we have conducted 
genome-wide surveys of edelfosine sensitivity 
and resistance in Saccharomyces cerevisiae 
presented in this work and the accompanying 
paper (Cuesta-Marbán et al), respectively. Our 
results point to maintenance of pH homeostasis 
as a major player in modulating susceptibility 
to edelfosine with the PM proton pump Pma1p 
playing a main role. We demonstrate that 
edelfosine alters PM organization and induces 
intracellular acidification. Significantly, we 
show that edelfosine selectively reduces lateral 
segregation of PM proteins like Pma1p and 
nutrient-H+ symporters inducing their 
ubiquitination and internalization. The biology 
associated to the mode of action of edelfosine 
we have unveiled includes selective 
modification of lipid raft integrity altering pH 
homeostasis which in turn regulates cell 
growth. 
________________________________________ 
The plasma membrane (PM) of eukaryotes 
represents one of the most complex 
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biomembranes, featuring an asymmetric lipid 
distribution between the two leaflets of the bilayer 
as well as lateral domain organization within 
leaflets. Lipid rafts are dynamic areas of the 
membrane rich in sterols and sphingolipids that 
serve as platforms for the association of membrane 
proteins. At the heart of the lipid raft concept lays 
the idea that the lipid environment is not passive 
but critical for regulation of protein function (1). 
In fact, it has been well documented that lipid rafts 
play important roles in membrane trafficking and 
signalling (1-3). Therefore alteration of these lipid 
domains is expected to interfere with these 
pathways, eventually leading to a detrimental 
impact on cell fitness and survival. This is in fact a 
proposed mode of action for the anticancer lipid 
drug edelfosine (4-8). 
The synthetic lipid edelfosine (1-O-
octadecyl-2-O-methyl-rac-glycero-3-
phosphocholine or ET-18-OCH3) is a prototypical 
member of a class of cancer chemotherapeutic 
drugs collectively known as alkyl-
lysophospholipid analogues or antitumor lipids. 
Edelfosine is similar to lysophosphatidylcholine 
but has greater metabolic stability due to the 
presence of ether-linked groups to its glycerol 
backbone. The mode of action of this drug is still 
controversial. Two cellular compartments have 
emerged as main targets of edelfosine, the plasma 
membrane and the endoplasmic reticulum (ER). 
At the plasma membrane edelfosine interacts with 
lipid rafts and induces changes in lipid and protein 
composition in these microdomains (6,9,10). On 
the other hand at the ER, edelfosine can induce ER 
stress (11,12) and inhibits phosphatidylcholine 
synthesis (13,14).  
The plasma membrane represents the first 
point of contact of edelfosine with cells. A major 
aspect of the anticancer activity of edelfosine lies 
in its selectivity to kill tumor cells, whereas 
normal cells are spared (9,15,16). Preferred uptake 
by cancer cells is thought to be crucial for its 
selective cytotoxicity (15,17,18). 
Much of what we know on how edelfosine 
enters cells comes from studies in budding yeast. 
Uptake of the drug in yeast is mediated by a 
flippase and controlled by the Lem3p subunit 
(6,19-21). Stimulated by the fact that edelfosine is 
cytotoxic to yeast at similar concentrations as 
those used to kill cancer cells, we initiated 
investigations to gain insight into its mode of 
action by performing unbiased genetic screens in 
this organism. A first screen provided evidence 
that edelfosine-mediated cytotoxicity is through 
modification of the biophysical structure of lipid 
rafts by inducing internalization of sterols and the 
essential proton pump Pma1p from the PM (6). In 
the present study and the accompanying paper 
(Cuesta-Marbán et al.) we expanded our genetic 
screen approach to survey the yeast deletion 
collection for sensitivity and resistance to 
edelfosine, respectively. The results of these 
screens further support a key role for lipid rafts 
and the essential proton pump Pma1p in mediating 
edelfosine cytotoxicity in yeast. In addition, our 
results unveiled an important role for trafficking 
pathways from and to the PM in modulating 
mechanisms of sensitivity and resistance to 
edelfosine. We also found that failure to maintain 
pH homeostasis may be the signal that regulates 
communication between the PM and intracellular 
membranes. 
 
EXPERIMENTAL PROCEDURES 
Yeast strains, plasmids and growth conditions 
Detailed information on yeast strains and 
plasmids used in this study is provided in Table 1. 
Yeast strains were grown on standard rich medium 
YPD (1% yeast extract, 2% Bacto-peptone, 2% 
glucose) or synthetic minimal medium (SD; 0.17% 
yeast nitrogen base without amino acids, 2% 
glucose). Amino acids were supplemented to SD 
medium according to the requirements of the 
strains used. Agar (2%) was added for solid plates. 
All yeast cultures were incubated at 30°C. Growth 
of cells treated with edelfosine was monitored by 
optical density at a wavelength of 600 nm (OD600). 
Growth medium pH was adjusted to values in the 
range of 3–7.5 as indicated, by addition of HCl or 
NaOH. Glucose (2%) was added from a 
concentrated sterile stock after the medium was 
autoclaved. 
 The VMA2, SNF1 and TRK1 genes 
including their own promoter and termination 
sequences were PCR amplified from genomic 
DNA obtained from the wild type strain BY4741. 
SalI and NotI sites were engineered in the forward 
and reverse primer respectively, to allow 
directional cloning into the centromeric plasmid 
3 
 
pRS315 (LEU2). Specific primers used are listed 
in Table 1. 
 
Identification of edelfosine-hypersensitive mutants 
in S. cerevisiae  
A total of 4672 different yeast deletion 
mutants, generated by the international deletion 
consortium (22,23) were obtained from Euroscarf. 
This collection of deletion mutants represents the 
total number of viable single mutants from a total 
of approximately 6,200 potential genes. All strains 
are derivatives of BY4741. The specific genes 
were disrupted with a kanamycin-resistant (kanR) 
cassette. Strains from the deletion collection were 
screened for hypersensitivity to edelfosine in solid 
medium. For this purpose strains were arrayed 
individually on a series of rectangular OmniTray 
agar plates (Nalgene Nunc International) at 384 
strains per plate and manipulated robotically using 
a Virtek Colony Arrayer (Bio-Rad). 
Edelfosine (the kind gift of Medmark 
Pharma GmbH and Inkeysa) was added to 
autoclaved synthetic defined (SD; 0.67% yeast 
nitrogen base without amino acids, 2% glucose 
and 2% agar and required supplements) medium 
cooled to  ~50°C. 
We and others have observed that the effect of 
lipids on cell growth in solid media can be 
affected by cell density (6,24). The robot pins a 
large number of cells in one spot so the 
concentration of edelfosine had to be increased 
from those normally used in serial dilution assays. 
For the chemical-genetic screen a final 
concentration of 190 μM edelfosine was used. 
This concentration did not affect growth of wild 
type (BY4741) colonies while it inhibited growth 
of a sensitive strain lacking Spo14p (25). Plates 
were incubated for 2 days at 30°C and imaged 
using a Versa Doc (Bio-Rad) apparatus. Colony 
size comparison on yeast array plates was 
determined using a scoring system as described 
(26). The screen was run four independent times. 
Genes identified at least three times out of the four 
runs are reported herein (Table 2). 
 
Data analysis and functional group classification  
Enrichment of data sets for Gene 
Ontology terms was performed using the Gene 
Ontology Term Finder at the Saccharomyces 
Genome Database (SGD, 
http://db.yeastgenome.org/cgi-
bin/GO/goTermFinder.pl) and the MIPS database 
(http://mips.helmholtz-
muenchen.de/genre/proj/yeast/ ). Interaction 
networks were visualized with Osprey using data 
from several databases (27). 
Funspec (28) was used to identify 
functional clusters of genes and statistical 
evaluation. Gene classification was done 
subjectively, supported by SGD, MIPS as well as 
the literature. 
 
Cytosolic pH measurements 
pYES-ACT-pHluorin plasmid (kindly 
provided by Gertien Smits from University of 
Amsterdam, The Netherlands) alongside an empty 
pYES vector (Invitrogen) used as control, were 
transformed into wild type or mutant yeast strains 
as indicated. pH determination was done 
according to the ratiometric method outlined by 
Orij et al. (29). Briefly, yeast transformants were 
grown to an OD600 of 0.5 at 30°C in modified 
synthetic media, lacking fluorescent compounds, 
p-aminobenzoic acid, riboflavin and folic acid, as 
well as uracil for plasmid selection. For pHluorin 
calibration, cells in PBS were treated with 100 
μg/ml of digitonin (Sigma) and resuspended in 
buffers with pH values ranging from 5.95-7.80. 
Fluorescence emission of pHluorin was measured 
at 512 nm in a Cary Eclipse Fluorescence 
Spectrophotometer (Varian) using excitation bands 
of 5 nm centered around 390 and 470 nm. The 
emission values were obtained using Cary Eclipse 
Ratio Application software; data and statistical 
analysis was done using Microsoft Excel and 
GraphPad Prism software. The ratio between 
emission intensities resulting from excitation at 
390 and 470 nm (R390/470) was plotted against 
the corresponding buffer pH to obtain standard 
curves for cytosolic pHluorin. In all experiments, 
the emission intensity values (background 
fluorescence) obtained from empty vector 
transformants were subtracted. pHluorin as well as 
empty plasmid transformants were treated with 19 
μM edelfosine and emission intensity ratios were 
calculated as described above. Fluorescence 
measurements were performed for treated and 
untreated cultures every 15 min during the first 
hour and at 90 min following initial addition of the 
drug. After the 90 min time interval, cells were 
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treated with 100 μg/ml digitonin for 15 min to 
equilibrate them to the external pH. All pH 
determination experiments were repeated at least 
three times, in quadruplicates for each sample. 
Figures show one representative experiment with 
error bars indicating the standard deviation of the 
four replicates within the experiment. 
 
Detergent-resistant membrane (DRM) isolation 
Yeast detergent resistant membranes 
(DRMs) were isolated as previously described (6). 
Briefly, log phase growing cultures at OD600 of 
0.1-0.2 in defined medium were incubated with or 
without 19 μM edelfosine for 2 hours at 30°C. 
Around 20 OD600 cell equivalents were collected, 
washed and resuspended in 500 μl of TNE buffer 
[50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5mM 
EDTA, protease inhibitor mixture (Roche), 2.5 
μg/ml pepstatin, 1 mM 
phenylmethanesulfonylfluoride]. Cells were 
broken in the presence of glass beads with a mini 
bead beater (Biospec) at maximum speed for 1 
minute at 4°C. Unbroken cell and debris were 
removed by a 500 X g spin for 5 min at 4°C. 
Protein concentration was determined (30) and 
300 μg of protein in 500 μl of TNE buffer was 
incubated with Triton X-100 (1% final 
concentration) for 30 min on ice. The lysate was 
subsequently adjusted to 40% Optiprep 
(Nycomed) by adding 1 ml of 60% Optiprep 
solution, overlaid with 2.4 ml of 30% Optiprep in 
TXNE (TNE with 0.1% Triton X-100), and then 
with 400 μl of TXNE. The samples were 
centrifuged at 166,000 X g for 2 h in a swinging 
bucket TLS55 rotor (Beckman). Ten fractions of 
equal volume were collected from the top of the 
gradient. The interface between the 0 and 30% 
Optiprep contained the DRMs and was easily 
identified optically and collected as fraction 2. An 
aliquot of each fraction was analyzed by 8% SDS-
PAGE followed by silver staining or western 
blotting as indicated. Proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes and 
blots were incubated with antibodies to Pma1p, 
Gas1p (the kind gifts of Ramón Serrano, 
Universidad Politécnica de Valencia and Howard 
Riezman, University of Geneva, respectively), or 
Pgk1p (Molecular Probes) and subsequently with 
horseradish peroxidase-conjugated secondary 
antibodies followed by detection using enhanced 
chemiluminescence. DRM isolations were 
performed ~20 times in different experimental 
conditions. 
 
Immunoprecipitation and protein analysis 
Cultures in 200 ml YPD were grown to an 
OD600 of 1.0 and edelfosine was added at 19 μM. 
Cells were treated for the indicated times, 
collected by centrifugation, and pellets were kept 
frozen until used. Cell lysis was achieved by 
resuspending pellets in 400 μl RIPA buffer (SDS 
0.1%, Triton X-100 1%, sodium deoxycholate 1%) 
plus inhibitors (10 μg/ml aprotinin and leupeptin, 
2 mM PMSF, 250 nM bortezomib, 10 mM 
iodoacetamide) and a similar volume of glass 
beads (0.5 mm diameter). The tubes were given 
three 15-sec pulses in a Fastprep, with 30 sec of 
cooling in between. Tubes were briefly spun-down 
to pellet the beads, the supernatants were 
transferred to new tubes and centrifuged for 5 min 
at 500 x g to pellet unbroken cells and debris. 
Protein concentration of the supernatants was 
determined in triplicate by using the Bradford 
assay. Pma1p was immunoprecipitated from 160 
μg of total protein with a rabbit polyclonal 
antibody raised against Pma1p (the kind gift of R. 
Serrano, Universidad Politécnica de Valencia, 
Spain), and 25 μl of CL-4B beads coated with 
protein A slurry (GE Healthcare) in 2 ml PBS 
overnight at 4ºC. Alternatively, 500 μg of protein 
were incubated in the same conditions with 20 μl 
of beads covalently bound to a ubiquitin-
interacting domain (Ubiquitinated Protein 
Enrichment Kit, Calbiochem). Beads were washed 
with PBS three times, resuspended in 30 μl of 
sample buffer and heated at 50ºC for 10 min to 
avoid Pma1p aggregation. Samples were directly 
loaded in discontinuous 7% polyacrylamide gels, 
which were then electroblotted. Membranes were 
probed with the anti Pma1p polyclonal antibody 
and a goat secondary antibody linked to Alexa680 
(Invitrogen) and imaged in a LiCor scanner.  
Alternatively, proteins were transferred to PVDF 
membranes (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK), and blots were incubated 
with antibodies to Pma1p or anti-ubiquitin 
(Invitrogen), and subsequently with horseradish 
peroxidase-conjugated secondary antibodies, 
followed by detection using enhanced 
chemiluminescence. 
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Microscopy 
 Filipin (Sigma) was used to examine sterol 
distribution as previously described (6). Filipin 
was freshly prepared as a 1 mg/ml stock in 
ethanol. Cells grown to log phase in defined 
medium, were treated with 19 μM edelfosine and 
aliquots of cells from the same culture were fixed 
at the indicated times with 3.7% EM-grade 
formaldehyde for 2 hours at room temperature. 
Fixed cells were centrifuged and washed twice 
with phosphate-buffered saline and spheroplasts 
prepared by treatment with zymolyase. Cells were 
then incubated with 10 μg/ml filipin in the dark for 
15 min at room temperature. Filipin fluorescence 
was observed with UV optics channel of a Zeiss 
Axiovert 200M microscope fitted with a plan-
neofluor 100x oil immersion objective lens. Pma1-
RFP was visualized using the rhodamine channel. 
Images were captured using a Zeiss Axio Cam HR 
and using Zeiss Axiovision Rel. 4.8 software. 
In the case of transformants carrying 
plasmids containing FUR4-GFP or FUR4-GFP-
DUb under the CUP promoter, expression was 
induced by addition of 100 μM CuCl2 into defined 
selective medium for 2 hours. At this point 
cultures were split in two and edelfosine was 
added to half of them at a final concentration of 19 
μM. Control and edelfosine cultures were then 
incubated for one hour at 30°C before preparation 
of slide for microscopy. Cells were then 
concentrated and placed on slabs of solid medium 
made from low fluorescent medium (as described 
above) and 2% agar. Coverslips were sealed and 
digital images were obtained using a Leica SP5 
Confocal Laser Scanning system (Leica, 
Germany). Fluorescence signals of RFP 
(excitation 543 nm, HeNe laser) were detected at 
emission range 565-635nm, and fluorescence 
signals of GFP (excitation 488 nm, HeNe laser) 
were detected at emission range 499-561 nm. 
Images were then aligned using Adobe Photoshop 
(7.0) software. At least 100 cells per condition 
were analyzed for quantification of microscopy 
images as indicated. Experiments were conducted 
at least 3 times. 
 
RESULTS 
  
Genes that control intracellular pH modulate 
sensitivity to edelfosine 
We performed a high-throughput 
edelfosine sensitivity screen by robotically pinning 
an ordered array of 4672 haploid yeast gene 
deletion mutants onto defined medium in the 
absence or presence of edelfosine (Fig. 1). Fifty 
four genes whose inactivation reproducibly 
resulted in increased sensitivity to edelfosine 
compared to wild-type were identified (Table 2). 
This data set was enriched in genes known to 
participate in pH homeostasis, regulation of 
transcription and lipid biosynthesis (Figs. 1 and 2). 
A cluster comprising genes coding for 9 of the 14 
subunits of the vacuolar proton-translocating 
ATPase (V-ATPase), as well as VPH2 and VMA21 
encoding proteins that participate in V-ATPase 
assembly in the ER (31), were identified (Table 2 
and Figs. 2, 3a). Serial dilution analysis expanded 
this result to include 12 V-ATPase subunits and 
one other gene coding for an assembly protein 
(VMA22) (Table 2 and Fig. 3a). In addition, TRK1, 
coding for the high affinity potassium transporter 
of the PM was among the genes identified (Table 
2 and Figs. 2, 3a). It is well documented that V-
ATPase in the vacuole collaborates with Pma1p at 
the PM to maintain pH homeostasis in yeast (32). 
Trk1 also participates in regulation of intracellular 
pH by positively regulating Pma1p activity (32-
34). 
The second largest category of enrichment 
in our screen contained genes that positively 
regulate transcription. Genes coding for the yeast 
AMP dependent kinase (AMPK) SNF1 and its γ 
subunit SNF4 were among these genes (Table 2, 
and Figs. 2, 3a). AMPK/Snf1p plays a central role 
in controlling energy homeostasis in eukaryotes 
(35). Snf1 responds to glucose depletion and is a 
modulator of Trk1 activity (36,37). Furthermore, 
cells deleted for SNF1 or SNF4 display pH-
dependent phenotypes (34,38). Deletion mutants 
vma2, trk1 and snf1 transformed with the 
corresponding wild type genes displayed wild type 
sensitivity to edelfosine (Fig 3b).  Therefore the 
hypersensitive phenotype is not due to secondary 
mutations present in these strains. 
The enrichment of genes related to 
maintenance of pH homeostasis in our sensitivity 
screen is in line with our previous findings 
involving Pma1p as the main target of edelfosine 
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interaction with the yeast PM. Since Pma1p is an 
essential protein, it was not expected to be found 
in the screen for edelfosine-sensitive mutants 
using the S. cerevisiae non-essential gene deletion 
collection. We tested the sensitivity of cells 
carrying a hypomorphic allele of PMA1, PMA1-
DAmP (Decreased Abundance by mRNA 
Perturbation) that results in substantially reduced 
levels of the protein (39). Consistent with our 
above results, PMA1-DAmP cells displayed 
increased sensitivity towards edelfosine (Fig. 3c), 
We hypothesized that edelfosine induced 
intracellular acidification, which in turn triggers a 
cellular response aimed at restoring pH 
homeostasis. Consequently cells impaired in 
maintenance of pH homeostasis would display 
increased susceptibility to edelfosine. 
 
Edelfosine induces intracellular acidification in 
yeast 
To assess the effect of edelfosine on 
intracellular pH we used a method based on the 
expression of ratiometric pHluorin (29). This 
protein is a pH-sensitive green fluorescent protein 
that has been successfully used to measure pH in 
yeast (29,32,40,41). To monitor the intracellular 
pH (pHi) of cells during treatment with edelfosine, 
cytosol targeted pHluorin was expressed in wild 
type cells as well as hypersensitive or resistant 
mutants vma2Δ and vps35Δ, respectively. Vma2p 
is a subunit of the vacuolar ATPase and its 
deletion resulted in strong sensitivity to edelfosine 
(Fig. 3a). On the other hand, Vps35p is a 
component of the yeast retromer and cells with an 
inactivated VPS35 gene are resistant to edelfosine 
while uptake of the drug is normal (see 
accompanying paper Cuesta-Marbán et al.). A 
time frame of 90 minutes was chosen as we have 
previously determined it precedes cell death (6). 
The cytosolic pH in wild type cells reached 
7.35±0.12 during the 90 min period but dropped to 
6.89±0.04 in the presence of edelfosine (Fig. 4). A 
steeper decline in pHi was observed in vma2Δ, 
dropping an extra 0.12-0.14 pH units after one 
hour treatment compared to wild type or vps35Δ in 
the same conditions (p<0.001 wt or vps35Δ vs. 
vma2Δ at 60 min Fig. 4). Conversely, the resistant 
mutant vps35Δ displayed a less pronounced drop 
in pHi during the same period of treatment (see 
accompanying paper Cuesta-Marbán et al.) (Fig. 
4). These results indicate that the buffering 
capacity of the cell influences its ability to handle 
the disturbance in pH homeostasis induced by 
edelfosine, further supporting an important role for 
intracellular acidification in mediating the 
cytotoxic activity of edelfosine in S. cerevisiae. 
We considered that if edelfosine 
compromises pH homeostasis an aggravated 
phenotype should be displayed when cells are 
grown under stress conditions where control of 
cytosolic pH is part of the adaptation response, 
like in tolerance to extreme external pH (pHext). 
The lower and upper pHext tolerance limits for 
yeast growth are 2.5 and 8 respectively (42). Due 
to a tight control of intracellular pH, the kinetics of 
growth and fermentation are not affected in pHext 
between 3.5 and 6.0 (42). We therefore decided to 
test sensitivity to edelfosine at pHext 3.0 and 7.5, 
which allow for significant cell growth despite 
causing considerable stress (41). The hypomorphic 
strain PMA1-DAmP was included in the analysis 
to monitor the impact that the chosen pH 
conditions have on a strain that should (partially) 
mimic the effect of edelfosine. A decrease in 
Pma1p activity and expression has been previously 
described in yeast grown at pH 2.5 and 3 (41,42). 
As expected, growth of the Pma1-DAmP strain 
was delayed when grown at pH 3 (Fig. 5 control 
plates 2 days). Interestingly, a similar delay was 
also observed in control plates at pHext 7.5 while 
no major differences were detected at pHext 5. As 
expected, edelfosine effect was stronger at pHext 3 
but surprisingly, it was even more potent at 
alkaline pHext 7.5 (Fig. 5, 3 days). These results 
suggest that additional compensatory pathway/s 
uniquely triggered by alkaline media are either 
impaired by treatment with edelfosine or result in 
enhanced sensitivity to the drug. 
 
Edelfosine induces ubiquitination of Pma1p 
We have previously shown that edelfosine 
induces sterol and Pma1p internalization in yeast, 
with Pma1p being internalized via endocytosis and 
then degraded in the vacuole (6). In the current 
work, co-localization studies using Pma1-RFP and 
filipin to detect sterol localization were performed 
(Fig 6a,b). Sterols and Pma1p were initially 
localized to the PM. Intracellular accumulation of 
sterols was evident after 30 minutes incubation 
with edelfosine. No intracellular co-localization 
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with Pma1p was observed at this time point (Fig. 
6b). The filipin signal became very weak at the 
PM by 50-60 min of treatment while the majority 
of the cells (77%) still displayed Pma1-RFP at the 
PM. Therefore, the kinetics of internalization of 
sterols and Pma1p as well as their intracellular 
localization differed. These results suggest that 
sterol internalization may precede Pma1p exit 
from the PM and that lipid and protein raft 
components are internalized through different 
routes (Fig. 6). Partitioning of Pma1p into 
detergent resistant membranes (DRMs), rich in 
sterols and sphingolipids is significantly reduced 
after treatment with edelfosine (Fig. 6 c-d).  
A Pma1p mutant (pma1-7) that fails to 
associate with sphingolipid and ergosterol-rich 
membrane microdomains en route to the PM is 
targeted to the endosomal/ vacuolar system (43) in 
a ubiquitin-dependent process (44). Since the 
effect of edelfosine resembles that of the pma1-7 
mutant, we then investigated if edelfosine would 
also induce Pma1p ubiquitination. In fact, when 
cell extracts were immunoprecipitated with protein 
A-Sepharose beads coupled to an antibody against 
Pma1p, an extra band with a molecular weight ~8 
kDa higher than the Pma1p band from untreated 
cells was observed at early time points (1-2 hours, 
Fig. 7 a). This is compatible with a 
monoubiquitination signal and was further 
supported by the immunoprecipitation of 
ubiquitinated proteins followed by Western blot 
using an anti-Pma1p antibody (Fig. 7b). 
Ubiquitinated Pma1p was readily detected after 
drug treatment, whereas it was absent in untreated 
cells (Fig. 7b). Analysis of total cell lysates 
suggests Pma1p is not the only protein being 
ubiquitinated upon treatment with edelfosine (Fig 
6c). Furthermore, the unbiased results from our 
chemogenomic screen testing for enhanced 
resistance to edelfosine (see accompanying paper 
Cuesta-Marbán et al.) identified genes involved in 
maintenance of the ubiquitin pool, E3-ubiquitin 
ligase adaptor proteins as well as mutants of 
pathways that recognize ubiquitinated cargo like 
the ESCRT and retromer systems. Together these 
results indicate that edelfosine induces exit of 
sterols and Pma1p from the PM followed by 
Pma1p internalization and degradation in an 
ubiquitin-mediated process. 
 
Edelfosine alters plasma membrane domain 
organization, inducing ubiquitination and 
internalization of nutrient H+-symporters 
The emerging picture of the yeast PM 
indicates it is highly organized displaying an 
intricate array of domains with most membrane-
associated proteins segregating into distinct areas 
(45,46). Different distribution patterns have been 
observed for PM proteins by fluorescence 
microscopy, ranging from “patch like” to 
“network” shaped as described for the eisosome 
protein Sur7p and the proton pump Pma1p, 
respectively (45-47). These differences observed 
in vivo are lost when crude fractionation 
approaches, like isolation of DRMs, are used. 
Notoriously, all yeast PM proteins analyzed to 
date associate with DRMs (47-50). Therefore the 
profile of PM proteins should be contained in that 
of DRMs. A comparison of the protein profile 
from control versus treated cells suggested that 
Pma1p was not the only protein disappearing from 
DRMs upon treatment with edelfosine [Fig. 6c and 
(6)]. We noticed that although the band 
corresponding to Pma1p was clearly affected, 
other bands also became fainter after edelfosine 
treatment (Fig. 6c, stars). This prompted us to 
analyze the effect of edelfosine on several well 
studied proteins that partition in a compartment 
that has been named MCC, for membrane 
compartment occupied by Can1 as opposed to 
MCP, the membrane compartment occupied by 
Pma1p (50,51). The first MCC protein analyzed 
was Sur7p, as it forms distinct, non overlapping 
domains with MCP (45). 
The effect of edelfosine treatment was 
studied by confocal microscopy using cells 
expressing Pma1p-RFP or Sur7p-GFP. While 
edelfosine induced internalization of Pma1p and 
its accumulation in the vacuole, Sur7p remained 
associated with the PM in a patch like distribution 
(Fig 8). Closer inspection of Sur7p in edelfosine 
treated cells revealed the formation of larger 
patches in the form of rings not observed in 
control cells (Fig. 8). The nutrient H+-symporters 
Can1p (arginine transporter) and Fur4p (uracil 
transporter) co-localize with Sur7p at MCC 
domains. Interestingly, in contrast to Sur7p and 
similar to Pma1p, edelfosine efficiently induced 
internalization of Can1p and Fur4p (Fig. 9 a, b). 
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These results indicate that edelfosine 
alters the organization of the yeast PM by 
selectively inducing the internalization of Pma1p 
as well as the MCC resident nutrient H+-
symporters Can1p and Fur4p, but not the structural 
eisosome protein Sur7p. 
Since ubiquitination of Fur4p is a known 
cell surface event that is required prior to 
internalization (52) investigations were conducted 
to test if this was also true in the case of treatment 
with edelfosine. We expressed Fur4p-GFP fused 
to the catalytic domain of the deubiquitinating 
peptidase Ubp7p (DUb) which has been shown to 
be a constitutive nonubiquitinatable form of Fur4p 
(53). These cells were also expressing Pma1p-RFP 
to allow colocalization studies. Cells were 
challenged with edelfosine and live cells imaged 
by confocal microscopy (Fig. 9c). In contrast to 
Pma1p-RFP and Fur4p-GFP the presence of the 
DUb catalytic domain abolished Fur4p 
internalization induced by edelfosine. It is worth 
noting that although Fur4p-GFP-DUb remained at 
the PM its distribution did indeed change, 
becoming patchier. A similar pattern was observed 
for Pma1p-RFP on the way to being internalized. 
Altogether these results indicate that 
internalization of nutrient H+-symporters like 
Fur4p depends on ubiquitination induced by 
edelfosine. They also suggest edelfosine induces 
lateral movement of PM proteins prior to 
ubiquitination. 
 
DISCUSSION 
 
Our findings clearly show that edelfosine 
alters the domain organization of the yeast plasma 
membrane by inducing changes in the distribution 
of lipids and proteins within domains. This in turn 
affects pH homeostasis, which emerged from this 
study as a major contributor to sensitivity towards 
edelfosine. Pma1p at the PM is a key regulator of 
pH homeostasis in yeast, and the displacement of 
Pma1p from lipid rafts appears to be a critical 
event that mediates edelfosine effect. Indeed, 
treatment with edelfosine induced intracellular 
acidification in wild-type yeast. In this context, 
cells defective in V-ATPase activity were more 
susceptible to edelfosine as this vacuolar H+-pump 
is known to collaborate with Pma1p in preserving 
a proper cytosolic pH (32). In fact, Pma1p is 
missorted to the vacuole in vma mutants (32), and 
it has been recently shown that aberrant cytosolic 
pH in these mutants is responsible for missorting 
of Pma1p and other cargo proteins from the Golgi 
(54). Thus, intracellular pH controls sorting of PM 
proteins and in the case of edelfosine mediates 
communication from the PM to internal 
compartments. Interestingly, the retromer vps35Δ 
mutant that is resistant to edelfosine displayed a 
higher buffering capacity (Fig. 4). This probably 
reflects recycling of Pma1p back to the PM upon 
treatment with edelfosine (see accompanying 
paper Cuesta-Marbán et al.).  
The functional categories of transporters 
and trafficking machinery were significantly 
enriched in a recent genome-wide survey of 
vacuolar pH under different stress conditions (55). 
These categories were also enriched in our 
resistance genetic screen presented in the 
accompanying paper (Cuesta-Marbán et al.). Of 
particular interest is the fact that the same 
phospholipid flippases mediating edelfosine 
uptake emerged as pH regulators, as did retromer 
and ESCRT mutants (55). This further highlights 
the role that intracellular pH plays in the 
communication between membranes in the cell. 
Our findings strongly support a proposed 
signalling role for cytosolic pH in the control of 
growth in yeast (41). 
Our current model of action of edelfosine 
in yeast starts with edelfosine inducing the 
internalization of sterols from the PM. Indeed, 
reduced accessibility of sterols to edelfosine 
alleviates its cytotoxic effect (7). We hypothesize 
that edelfosine induces changes in the sterol 
retention capacity of the PM (56) by interfering 
with the interaction between sterols and 
sphingolipids (57). Perturbation of lipid 
composition of the PM and reduction in lipid 
complexity has in fact been associated with 
reduced protein segregation (45). We show in this 
study that segregation of several transporters 
including Pma1p, Can1p and Fur4p, is affected by 
edelfosine. These proteins act in consortium with 
Pma1p producing the proton motive force that is 
consumed by nutrient-H+-symporters like Can1p 
and Fur4p (47). Displacement of transport proteins 
leads to their ubiquitination, internalization and 
vacuolar degradation. In contrast, Sur7p a 
structural protein of eisosomes, remained at the 
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PM after treatment with edelfosine. A similar 
scenario to the one depicted by edelfosine was 
observed upon induction of PM depolarization. 
MCC resident H+-symporters, including Can1p 
and Fur4p, moved out of MCC patches together 
with ergosterol resulting in growth inhibition 
(58,59). Under the same conditions Sur7p 
localization remained unaffected (58,59). 
Edelfosine triggers ubiquitination of 
proteins, including Pma1p (Fig 7). Furthermore, 
we show herein that internalization of Fur4p 
induced by edelfosine is also mediated by 
ubiquitination, as the nonubiquitinatable form of 
Fur4p remains at the PM (Fig 9). Fur4p has been 
extensively studied and it is known that its sorting 
to the endosomal system is controlled by Rsp5p-
dependent ubiquitination which also involves the 
adaptor proteins Bul2p and Bsd2p (60-63). Rsp5p 
is an E3 ubiquitin ligase and the null mutant is 
absent from the yeast deletion collection used in 
our chemogenomic screens. Interestingly, the 
genes coding for the Rsp5p protein adaptors BUL2 
and BSD2 were identified in our resistance screen 
(see accompanying paper Cuesta-Marbán et al.) 
suggesting they could mediate ubiquitination of 
Fur4p and other proteins in response to the 
changes in the PM introduced by edelfosine.  
It is not clear at this point if changes in 
intracellular pH could be sensed by the 
ubiquitination machinery. In this regard it is 
interesting to note that mutations in the PMA1 
gene have been found to suppress the temperature 
sensitivity phenotype of rsp5 mutants (64). It is 
worth highlighting that the changes in lateral 
segregation of proteins targeted for internalization 
seem to precede ubiquitination, as Fur4-GFP-DUb 
alters its PM distribution upon treatment with 
edelfosine, coinciding with that of Pma1p en route 
to being internalized (Fig 9). 
Snf1p, the AMPK yeast ortholog, sits at 
the intersection of distinct organelles, including 
the vacuole, mitochondria and nucleus (65). The 
interactome map for genes identified in our screen 
shows that SNF1 and SNF4 intersect many of them 
(Fig. 2), providing a link between the different 
functional categories enriched in our screen.  
Snf1p senses ATP availability and 
controls cellular metabolism regulating the switch 
from fermentation to respiration, a condition 
known to induce a rapid drop in intracellular pH 
(32). Our results indicate that signaling through 
Snf1p modulates sensitivity of yeast to edelfosine. 
It is worth noting that fermentation is 
characteristic of cancer cells and therefore the role 
of AMPK in the cellular response to edelfosine 
may be similar in cancer cells as in yeast (35). In 
this regard, we observed that susceptibility of 
wild-type yeast to edelfosine increases in the 
presence of non-fermentable or semi-fermentative 
carbon sources, like glycerol and galactose, 
respectively (not shown). Interestingly, growth on 
galactose or glycerol induces cytosolic 
acidification (29), and we suggest that this lower 
pH threshold, analogous to vma, trk1 and pma1 
mutants, causes increased sensitivity to edelfosine. 
Furthermore, it has been reported Snf1p is a 
possible modulator of Trk1p. Cells lacking Snf1p 
and Snf4p are sensitive to acidic pH and this 
depends on lipid metabolism (34). Snf1 also plays 
a critical role in response to alkaline pH stress 
(38).  
Edelfosine sensitivity was exacerbated at 
acidic pHext, and interestingly was also 
aggravated at a slightly alkaline pHext. We 
speculate that edelfosine may also affect proper 
partitioning of high affinity glucose transporters 
(i.e Hxt2p) as well as iron and copper transporters 
into their unique coexisting microdomains at the 
PM (45). Uptake of glucose, iron and copper has 
been shown to be critical to improve fitness of 
yeast at alkaline pH (38,66). In addition, a critical 
role for Snf1 in tolerance to alkalinization due to 
the function of this kinase in regulating the switch 
from fermentative to respiration metabolism has 
been proposed (38,65). This switch to respiration 
may also be responsible for the stronger effect of 
edelfosine in alkaline pH. In line with this 
rationale a novel role for mitochondria in 
maintenance of pH homeostasis has been recently 
unveiled (41). Furthermore, our resistance genetic 
screen was enriched in mitochondrial functional 
categories (see accompanying paper Cuesta-
Marbán et al.), suggesting impaired respiration 
alleviates edelfosine sensitivity. Another 
possibility is that edelfosine, or its effect on 
intracellular ergosterol accumulation may affect 
proper V-ATPase assembly/ function which is 
expected to confer susceptibility to high pHext 
(41,55). In support of this hypothesis a 
requirement of ergosterol for proper V-ATPase 
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function has been established (67). Finally, uptake 
of edelfosine may be enhanced at alkaline pH. It is 
worth noting that expression of Drs2p, one of the 
yeast flipases, is augmented in response to high 
pHext (66). Experiments are underway to test 
these possibilities. 
All the changes induced by edelfosine at 
the PM occur within the first hour of treatment and 
up to this point are reversible, as cell viability is 
not compromised (6,7). We have noticed uptake of 
choline, cysteine and methionine decrease within 
30 minutes of incubation with edelfosine (6). This 
probably suggests a more general effect of 
edelfosine on nutrient-uptake leading to a 
quiescent phase of growth. Therefore, we propose 
that during the first hour, the effect of edelfosine is 
mostly cytostatic due to lack of nutrient uptake. 
After one hour edelfosine uptake reaches a 
maximum and accumulates in the endoplasmic 
reticulum [(6) and accompanying paper Cuesta-
Marbán et al.)]. Therefore, cells that can correct 
the changes induced by edelfosine at the PM 
would be able to resume growth despite the 
intracellular accumulation of edelfosine. This is 
the behaviour we have noticed for strains that were 
able to recycle Pma1p back to the PM due to 
slower endocytosis and decreased protein 
degradation (6). 
Our work clearly identifies the plasma 
membrane as the first target of edelfosine action. 
Uptake of edelfosine into the plasma membrane of 
cells alters sterol organization that in turn affects 
the organization of specific proteins that reside in 
sterol enriched domains inducing a quiescent 
growth phase. Many of the PM transporters 
affected pump protons into and out of the cell with 
the end result being a reduction in cytoplasmic pH 
and eventually cell death. The buffering capacity 
of cells and their ability to restore pH homeostasis 
is critical for edelfosine efficacy. 
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Table 1- Strains, plasmids, and primers used 
 
 
Strain  Genotype Reference 
BY4741 MATa his3 leu2 met15 ura3 Euroscarf 
YMS084 MATα can1∆::MFa1pr-HIS3-MFα1pr-LEU2 his3∆0 leu2∆0 
ura3∆0 met15∆0 lyp1∆0 
(39) 
PMA1-DAmP YMS084 YGL008C::3NATB (39) 
W303-1a MATa ura3-1 his3-11,15 leu2-3,112 trp1-1 ade2-1 can 1-100  
Sur7-GFP W303 Sur7-GFP::HIS3  (68) 
SEY6210 MATα ura3-52 leu2-3,112 his3-∆100 trp1-∆901 lys2-801 suc2-∆9 (47) 
Pma1-RFP SEY6210 PMA1::tdimer2 (12) ::kanMX4 (47) 
Pma1RFP/ 
Can1GFP 
SEY6210 PMA1::tdimer2(12)::kanMX4CAN1::GFP::kanMX4  (47) 
Plasmid Description  
Fur4-GFP pRS315 expressing Fur4-GFP from CUP1 promoter (53) 
Fur4-GFP-Dub pRS316 expressing Fur4-GFP-Ubp7CD from CUP1 promoter (53) 
Cytosolic 
pHluorin 
pYES expressing pHluorin from ACT1 promoter (29) 
VMA2 pRS315 expressing Vma2 from its own promoter this study 
TRK1 pRS315 expressing Trk1 from its own promoter this study  
SNF1 pRS315 expressing Snf1 from its own promoter this study 
Primers   
VMA2 VMA2-F GAGAGTCGACGGTACGTGGTAGGCTAGAGTG 
VMA2-R GAGAGCGGCCGCCGCTTGATGTGCCCAGGGTGA 
 
TRK1 TRK1-F GAGAGTCGACGGGCACGAATTATGACAGAGTA 
TRK1-R GAGAGCGGCCGCACTAATGGCGTTGACGATGACG 
 
SNF1 SNF1-F GAGAGTCGACGCAGGCTATGATGTCCCATATG 
SNF1-R GAGAGCGGCCGCTTCTGCCTGGTCTTTATTCAT 
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Table 2- Complete list of genes identified in our genetic screen. Genes discussed in this work are in bold 
 
Sensitivity Gene Cellular role Localization
+++ AFG3 Protein phosphorylation mitochondria
+++ BEM1 Cell organization and biogenesis bud tip-bud neck-cell periphery
+++ DBF2 Protein phosphorylation bud neck-cytoplasm
+++ ERG3 Lipid metabolism ER
+++ GAL11 Transcription nucleus
+++ HTA3 (HTZ1) Chromatin remodeling nucleus
+++ PGD1 Transcription nucleus
+++ REI1 Translation cytoplasm-ribosome
+++ SIN3 Chromatin remodeling mitochondria-nucleus
+++ SIP3 Energy homeostasis nucleus
+++ SNF1 Energy homeostasis nucleus-mitochondria-vacuole-cytoplasm
+++ SNF2 Chromatin remodeling nucleus
+++ SNF6 Chromatin remodeling nucleus
+++ SPT7 Transcription nucleus-mitochondria
+++ VMA16 (PPA1) Vacuolar ATPase vacuole
+++ VMA2 Vacuolar ATPase vacuole
+++ VMA4 Vacuolar ATPase vacuole
+++ VMA5 Vacuolar ATPase vacuole
+++ VMA9 Vacuolar ATPase vacuole
+++ VPH2 (VMA12) Vacuolar ATPase assembly ER
+++ YJL175W Chromatin remodeling probably SWI3 (nucleus)
++ AKR1 Protein pamitoylation golgi
++ ASC1 Translation cytosol-ribosome
++ BIM1 Cell organization and biogenesis microtubule
++ COX17 Cytochrome C assembly mitochondria-nucleus?
++ CYC2 Cytochrome C regulation mitochondria
++ DEF1 Protein degradation nucleus-cytoplasm
++ ELO2 Lipid metabolism ER
++ ETR1 Lipid metabolism mitochondria-nucleus
++ LIP5 Lipid metabolism mitochondria
++ NAP1 Chromatin remodeling nucleus-cytoplasm
++ PAA1 Chromatin remodeling cytoplasm
++ PDA1 Acetyl-CoA production (impact on lipid metabolism) mitochondria
++ RPB4 Transcription nucleus
++ SEC22 Vesicular transport golgi-ER
++ SER1 Serine metabolism- (impact on lipid metabolism) cytoplasm
++ SHY1 Cytochrome C assembly mitochondria
++ SNF4 Energy homeostasis nucleus-PM-cytoplasm
++ SNF5 Chromatin remodeling nucleus
++ SPF1 Ion transport (P-type ATPase) ER-mitochondria
++ SPO14 Lipid metabolism endosomes?
++ SRB2 Transcription nucleus-cytoplasm
++ SUR4 Lipid metabolism ER
++ SWI6 Transcription nucleus-cytoplasm
++ TRK1 pH homeostasis and K+ transport PM
++ UBP6 Protein degradation nucleus-cytoplasm
++ VMA10 Vacuolar ATPase vacuole
++ VMA11 (TFP3) Vacuolar ATPase vacuole-ER
++ VMA21 Vacuolar ATPase assembly vacuole
++ VMA7 Vacuolar ATPase vacuole
++ YBR178W Lipid metabolism probably EHT1 (mitochondria-lipid particle)
++ YDR521W Transcription probably YDR520C (nucleus)
+ PDX3 Lipid metabolism ?
+ VMA6 Vacuolar ATPase vacuole  
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Figure legends 
 
Figure 1: High-throughput edelfosine S. cerevisiae sensitive screen. (a) The complete set of haploid S. 
cerevisiae yeast deletion mutants (~4,800 strains) was arrayed onto 20 plates and robotically pinned onto 
SD media (computerized colored green colonies) or SD + edelfosine (computerized colored red colonies). 
Putative edelfosine-sensitive mutants lead to the formation of smaller colonies (or no colony) when grown 
on edelfosine containing media (green after overlay, arrow); (b) Functional distribution of the 54 genes 
found to cause sensitivity to edelfosine when deleted. The functional categories corresponding to vacuolar 
acidification and ion transport, grouped as V-ATPase & pH homeostasis in the figure, had the lowest p-
values (2.784e-12 and 3.099e-08 respectively, Funspec analysis) indicative of a significant enrichment; 
(c) Enrichment of genes in our dataset clustering according to gene ontology (GO). Enrichment is 
calculated relative to the frequency of that cluster in the whole genome. 
 
Figure 2: Interactome map of genes identified in edelfosine sensitive screen. Nodes represent genes 
identified as hypersensitive to edelfosine in our screen. Genes belonging to the same pathway or complex 
are coloured according to the categories shown at the bottom of the figure. Edges indicate experimentally 
determined genetic or physical interactions. Nodes with a minimum of one connection are shown. 
 
Figure 3: Mutants with compromised pH homeostasis are hypersensitive to edelfosine. Strains 
scored as sensitive at least three times (from four screens completed) were verified by spotting serial 
dilutions of the cells onto media containing 19 μM edelfosine. Thus, a total of 54 deletion strains were 
confirmed to be edelfosine sensitive. (a) The analysis was extended to all known V-ATPase-related genes 
by spotting serial dilutions of their corresponding deletion strains onto rich (YPD) medium control or 
plates containing 19 μM edelfosine (EDLF). Plates were incubated at 30°C for 3 days. Data shown are 
representative of three independent experiments. (b) Deletion strains vma2, trk1 and snf1were 
transformed with empty pRS315 (CEN) plasmids or same plasmids containing the corresponding wild 
type gene under their own promoters. Sensitivity to edelfosine was reverted to that displayed by the 
isogenic wild type strain (BY4741) transformed with the empty plasmid. (c)The yeast strain with the 
PMA1-DAmP (Decreased Abundance by mRNA Perturbation) allele displays increased sensitivity to 
edelfosine. 
 
Figure 4: Edelfosine treatment leads to intracellular acidification. Cytosolic pH measurements were 
performed using pHluorin, as described in Experimental Procedures. (a) Intracellular pH was monitored 
during a 90 min period in control (open squares) or edelfosine (19 µM) treated cells (closed squares). 
Time course shown for wild type (BY4741), the resistant retromer mutant vps35Δ and the hypersensitive 
V-ATPase mutant vma2Δ; (b) Comparison of the values obtained after 90 min treatment. Data shown are 
mean values ± SD representative of three independent experiments. Asterisks indicate values that are 
significantly different from untreated control cells at p < 0.001 (***),p< 0.01(**) and p< 0.05 (*). 
 
Figure 5: Edelfosine sensitivity at various external pH conditions. The yeast strain PMA1-DAmP and 
its isogenis wild type were grown to log phase in defined medium (pH 5.2) and then serial diluted in 
plates containing the indicated concentrations of edelfosine at different external pH of 3, 5 or 7.5. Plates 
were incubated at 30°C for 3 days. Data shown are representative of three independent experiments. 
 
Figure 6: Edelfosine induces multiple changes in lipid raft organization. (a) Cells expressing Pma1p-
RFP were treated with edelfosine (19 µM) or just vehicle (control) for 50 min at 30°C followed by a 5 
min staining with filipin to visualize sterols. Arrows point to an area of the PM enriched in Pma1p-RFP 
that seems to be partially surrounded by sterols on the intracellular side. Note: lack of Pma1-RFP signal 
in growing areas of the plasma membrane of budding yeast (areas containing newly synthesized Pma1-
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RFP) is due to the slow maturation of the RFP fluorophore although the protein is present in those areas 
(47) (b) Time course of sterols and Pma1 internalization during treatment with edelfosine (19  µM) in 
fixed cells (c-f) Wild type (BY4741) cells were treated with edelfosine (19 µM) for two hours in defined 
medium at 30°C. DRMs were prepared as indicated in Experimental Procedures. Silver staining (c) 
showing whole protein profile and western blot for Pma1p (d). The most prominent change induced by 
edelfosine is the decrease in the abundance of Pma1p from DRMs. Several other proteins are also affected 
by treatment with edelfosine. Stars denote proteins that decrease while arrows indicate protein bands that 
increase their presence. Several other bands do not change. The protein profile associated with DRMs 
changes according to growth conditions, incubation times and edelfosine concentration. This is a 
representative experiment from at least 20 performed in similar or different conditions [see also protein 
profile from three different genetic backgrounds from reference (6)]. (e) Western blot analysis of Pma1p, 
Gas1p (GPI-anchored protein that partitions into DRMs) and Pgk1p (cytosol) showing the distribution of 
all three proteins in the entire gradient. (f) Western blot analysis of the same proteins as in (e) in whole 
cell lysate samples (loading control). 
 
Figure 7: Edelfosine induces Pma1p ubiquitination (a) Pma1p immunoprecipitation allows for 
detection of a discrete band ~ 8 kDa larger than Pma1p (arrow) upon edelfosine (EDLF) treatment which 
could account for ubiquitinated species (upper). Coomassie-stained gels (lower) are shown as loading 
control. (b) Immunoprecipitation of total ubiquitinated proteins leads to detection of Pma1p (arrow) by 
western blot only in edelfosine (EDLF)-treated samples; (c) Wild type (BY4741) cells were grown in the 
absence or presence of edelfosine (19 μM) in defined medium for 2 hours at 30°C. Cells were collected 
and lysates prepared. Fifteen μg of total protein from each sample were separated by SDS-PAGE and 
blotted against ubiquitin (left panel) or Pma1p (right panel). 
 
Figure 8: Edelfosine does not induce internalization of the MCC resident protein Sur7p. (a) Cells 
with endogenously expressed Pma1p-RFP (top) or Sur7p-GFP (bottom) were grown to log phase in the 
absence (control) or presence of edelfosine (19 μM) for 1 hour at 30°C. Arrows indicate changes in the 
distribution pattern of Sur7p after treatment with edelfosine. (b) Quantitation of at least 100 cells from 
each condition. PM, plasma membrane; IC, intracellular. 
 
Figure 9: Edelfosine induces internalization of nutrient-H+ symporters Can1p and Fur4p of the 
MCC; ubiquitination of Fur4p by edelfosine. Cells co-expressing Pma1p-RFP and either Can1p-GFP, 
Fur4p-GFP or Fur4p-GFP-Dub were grown to log phase in the presence or absence of edelfosine (19 μM) 
for 1 hour at 30°C before imaging using confocal microscopy. (a) Pma1p (MCP) and Can1p (MCC) are 
internalized upon treatment with edelfosine. (b) Pma1p (MCP) and Fur4p (MCC) are internalized upon 
treatment with edelfosine. (c) Fusion of the catalytic domain of Ubp7p (DUb) to the carboxy-end of 
Fur4p-GFP (53) prevents internalization of Fur4p while Pma1p still gets internalized upon treatment with 
edelfosine. Arrows point to the co-localization of Pma1p and Fur4p-GFP-Dub in large patches at the PM 
induced by edelfosine. Such distribution is absent from control cells. (d) Quantitation of at least 100 cells 
from each condition. PM, plasma membrane; IC, intracellular. 
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